REVIEW article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1594100
This article is part of the Research TopicEarly Detection, Cancer Interception, Et Al: Translating the Multifaceted Use of Liquid Biopsy to the Management of Early DiseaseView all 6 articles
Clinical Utility of Various Liquid Biopsy Samples for the Early Detection of Ovarian Cancer: A Comprehensive Review
Provisionally accepted
- 1Department of Gynecology and Obstetrics, First Affiliated Hospital of Xi ‘an Jiaotong University, Xi'an, China
- 2School of Medicine, Northwest University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ovarian cancer (OC) is a highly lethal gynecologic malignancy because of the absence of specific early symptoms and reliable biomarkers, most OC patients are often diagnosed at advanced stages, resulting in poor prognosis. Traditional tissue biopsy and serological biomarkers like CA125 have limited clinical application. Therefore, there is an urgent demand for effective diagnostic and screening tools in clinical practice. Liquid biopsy is a non-invasive method for early cancer detection by analyzing tumor-associated components shed into different body fluids, for example, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free RNA, proteins, and metabolites.Increasing evidence has demonstrated that liquid biopsy is promising for detecting cancer at an early stage. In this review, we outline the results for the utility of each liquid biopsy fluid, including serum/plasma, urine, cervical/vaginal sample, uterine lavage, and summarize the advantages and current constraints associated with their application in clinical settings. Future directions and challenges are also highlighted, along with areas where more research is warranted.
Keywords: ovarian cancer, Early detection, liquid biopsy, biomarkers, multi-omics
Received: 15 Mar 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 Feng, Yang, Zhu, Wang, Ningjuan, Zhao and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaofeng Yang, Department of Gynecology and Obstetrics, First Affiliated Hospital of Xi ‘an Jiaotong University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.